Decompensated cirrhosis is characterized by a systemic pro-inflammatory and pro-oxidant milieu that plays a significant role in developing multiorgan dysfunction. Recent clinical trials suggest that long-term albumin administration to patients with decompensated cirrhosis improves survival, prevents complications, simplifies the management of ascites, and reduces hospitalizations, thus being cost-effective. In this regard, PlasmaGen BioSciences and Docplexus have organized a clinically insightful session where Prof. Mauro Bernardi (Italy) and Dr. Anurag Shrimal (India) will provide an overview of the management of liver cirrhosis with albumin.
The session will be moderated by Dr. Narendra Patil (Singapore). Join us on May 28 th , 2022, at 7:00 PM IST to learn more. We look forward to your active participation in this informative discussion. Agenda Reference: Bernardi M, Angeli…
